Companies: 10,795·Total market cap: $144.5T
Boston Therapeutics, Inc.

Boston Therapeutics, Inc.

BTHEOTCHealthcare
$0.01
+$0.00(+0.00%)
Market Cap$0
P/E Ratio—
52W High$0.0119
52W Low$0.0091
Overview

Boston Therapeutics, Inc. (BTHE) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001473579 · BTHE · OTC · as of Jun 9, 2026

Filing snapshot

307
Total Filings
REVOKED
Latest Form
2025-04-09
Most Recent
2012
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001473579 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2023-04-07
Fiscal Year End
Apr 7, 2023
Accession No.
0001213900-23-028171
Primary Document
f10k2022_nanomixcorp.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001473579 · Accession 0001213900-23-028171

Latest Key Filings

10-QQuarterly Report
QUARTERLY REPORT
2022-11-14
View 10-Q on SEC
8-KCurrent Report
CURRENT REPORT
2023-11-24Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
REVOKEDREVOKED
REVOKED
2025-04-09
View
SC 13G/ABeneficial Ownership Report (Amended)
NNMX 13G/A
2024-11-08
View
SC 13G/ABeneficial Ownership Report (Amended)
NNMX 13GA
2024-02-06
View
8-KCurrent Report
CURRENT REPORT
2023-11-24
View
NT 10-QNT 10-Q
NOTIFICATION OF LATE FILING
2023-05-15
View
10-KAnnual Report
ANNUAL REPORT
2023-04-07
View
NT 10-KNT 10-K
NOTIFICATION OF LATE FILING
2023-03-31
View
8-KCurrent Report
FORM 8-K
2023-03-10
View
SC 13G/ABeneficial Ownership Report (Amended)
NNMX 13GA
2023-02-10
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2023-01-26
View
8-KCurrent Report
CURRENT REPORT
2023-01-25
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2022-12-21
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2022-12-19
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2022-12-19
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2022-12-16
View
Showing 1–15 of 271 filingsForm 4 / 144 hidden· 307 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001473579  |  Exchange: OTC · Healthcare

Boston Therapeutics, Inc. (OTC: BTHE) has submitted 307 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2012. As a Healthcare sector company with CIK 0001473579, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Boston Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Boston Therapeutics, Inc. 10-K was filed on 2023-04-07 for fiscal year ending 2023. Historical BTHE 10-K annual reports are available from 2010 through 2023.

Investors researching Boston Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
AVEFF SEC Filings →BNOEF SEC Filings →MXDHF SEC Filings →HBCNF SEC Filings →TBPMF SEC Filings →IMUN SEC Filings →FWPAY SEC Filings →POLXF SEC Filings →
→ BTHE Financials→ BTHE Earnings→ BTHE Insider Trades

Frequently Asked Questions

BTHE SEC Filings · 8 questions

Boston Therapeutics, Inc. (BTHE) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 307 filings and access original documents at no cost. Boston Therapeutics, Inc.'s CIK is 0001473579.

BTHE SEC filingsBoston Therapeutics, Inc. SEC documentsfind BTHE 10-K